Barclays PLC Has $304,000 Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Barclays PLC lifted its holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 391.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 193,873 shares of the biopharmaceutical company’s stock after acquiring an additional 154,436 shares during the quarter. Barclays PLC’s holdings in Lexicon Pharmaceuticals were worth $304,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of LXRX. FMR LLC raised its position in Lexicon Pharmaceuticals by 28.9% in the 3rd quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company’s stock worth $78,291,000 after purchasing an additional 11,179,919 shares during the last quarter. Point72 Asset Management L.P. raised its position in Lexicon Pharmaceuticals by 605.2% in the 2nd quarter. Point72 Asset Management L.P. now owns 4,121,191 shares of the biopharmaceutical company’s stock worth $6,924,000 after purchasing an additional 3,536,805 shares during the last quarter. Nantahala Capital Management LLC bought a new position in Lexicon Pharmaceuticals in the 2nd quarter worth approximately $3,871,000. Marshall Wace LLP raised its position in Lexicon Pharmaceuticals by 138.5% in the 2nd quarter. Marshall Wace LLP now owns 1,190,448 shares of the biopharmaceutical company’s stock worth $2,000,000 after purchasing an additional 691,276 shares during the last quarter. Finally, BBR Partners LLC raised its position in Lexicon Pharmaceuticals by 74.1% in the 3rd quarter. BBR Partners LLC now owns 470,000 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 200,000 shares during the last quarter. 74.70% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on LXRX. Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday, December 23rd. Leerink Partners set a $6.00 target price on shares of Lexicon Pharmaceuticals and gave the company an “outperform” rating in a research report on Friday, October 18th. Finally, HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Lexicon Pharmaceuticals in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Lexicon Pharmaceuticals has an average rating of “Hold” and an average price target of $6.00.

Lexicon Pharmaceuticals Stock Performance

Shares of Lexicon Pharmaceuticals stock opened at $0.79 on Monday. The firm has a fifty day moving average of $0.96 and a two-hundred day moving average of $1.49. The stock has a market capitalization of $194.18 million, a price-to-earnings ratio of -1.05 and a beta of 1.06. Lexicon Pharmaceuticals, Inc. has a 52 week low of $0.62 and a 52 week high of $3.73. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. The firm had revenue of $1.75 million during the quarter, compared to analyst estimates of $3.14 million. During the same period last year, the firm earned ($0.21) EPS. As a group, equities research analysts predict that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current year.

Lexicon Pharmaceuticals Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.